Trial Profile

A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Privosegtor (Primary)
Indications Glaucoma; Multiple sclerosis; Optic neuritis
Focus Adverse reactions
Sponsors Accure Therapeutics; Bionure

Most Recent Events

01 Mar 2021 Results published in the Accure Therapeutics Media Release.
15 May 2019 According to a Bionure media release, this study was conducted under the approval of the MHRA, UK.It was backed by a Series A financing led by Alta Life Sciences.
09 Apr 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com